Please View using PC
Disclaimer

I understand that this information is strictly for healthcare professionals only and that all of the materials contained herein shall not be shared to any non-healthcare professionals. I hereby confirm that I'm a qualified healthcare professional.

MANAGEMENT OF T2DM

Recommendation from ADA Standards of Care in Diabetes - 2024

Select therapies with adequate efficacy to achieve and maintain treatment goals (Glycemic, Weight, and CV risk reduction)

Summary
Glycemic Efficacy Hypoglycemia Weight loss Effect on MACE
Star GLP-1 RA High - Very high No Intermediate to very high Benefit
Metformin High No Neutral Potential benefit
SGLT2-i Intermediate - High No Intermediate Benefit
DPP-4i Intermediate No Neutral Neutral
SU High Yes Gain Neutral
Insulin High – Very high Yes Gain Neutral
Star
Glycemic Management

Very high
glucose-lowering efficacy

Arrow

Semaglutide, Dulaglutide (high dose), Tirzepatide, insulin, combination oral, combination injectable (GLP-1 RA / Insulin)

High glucose-
lowering
efficacy

Arrow

GLP-1 RA (not listed previously), Metformin, SGLT2i, Sulfonylurea, TZD

Intermediate
glucose-lowering efficacy

Arrow

DPP-4i

Remember: Avoidance of hypoglycaemia should be a priority in high-risk individuals.

Star
Weight-Management

Very high
weight-lowering efficacy

Arrow

Semaglutide, Tirzepatide

High weight-
lowering efficacy

Arrow

Dulaglutide, Liraglutide

Intermediate
weight-lowering efficacy

Arrow

GLP-1 RA (not listed previously), SGLT2i

No effect
on weight

Arrow

DPP-4i, Metformin

Consider regimen with high to very high dual glucose and weight lowering efficacy

Contact Us

If you wish to know more about Semaglutide (GLP-1 RA), please fill up the details below and a sales representative from Novo Nordisk will be in contact with you.

Please enable JavaScript in your browser to complete this form.

CVD: Cardiovascular disease; DPP-4i: Dipeptidyl Peptidase-4 Inhibitor, GLP-1 RA: Glucagon-Like Peptide-1, MACE: Major adverse cardiovascular events; SGLT2i: Sodium-Glucose Cotransporter-2 Inhibitor; SU: Sulfonylureas; TZD: Thiazolidinedione.

^ Low-dose TZD may be better tolerated and similarly effective

Extracted from Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). For full description, please refer to complete guidelines

SG24RYB00027